These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
    Author: Hyman AL, Kadowitz PJ.
    Journal: J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724.
    Abstract:
    The pulmonary vascular effects of the newly discovered prostacyclin metabolite, 6-keto-prostaglandin E1 (6-keto-PGE1) were investigated in the intact-chest cat. Intrapulmonary injections of 6-keto-PGE1 decreased lobar arterial prefusion pressure in a dose-dependent manner. Inasmuch as pulmonary blood flow was held constant, and left atrial pressure was unchanged, the fall in lobar vascular resistance. Decreases in lobar arterial pressure in response to 6-keto-PGE1 were greatly enhanced when tone in the pulmonary vascular bed was increased by infusion of a stable prostaglandin endoperoxide analog. 6-Keto-PGE1 decreased systemic arterial pressure increased cardiac output and reduced systemic vascular resistance in the cat. Decreases in systemic arterial pressure and systemic vascular resistance were similar when 6-keto-PGE1 was injected into the right or left atrium, suggesting that the substance is not converted to less active metabolites in passage through the feline pulmonary vascular bed. 6-Keto-PGE1 reversed the hypertensive effects of ADP in the pulmonary vascular bed suggesting this agent may inhibit ADP-induced platelet aggregation in small intrapulmonary vessels. These data indicate that 6-keto-PGE1 has marked vasodilator activity in the feline pulmonary and systemic vascular beds and since 6-keto-PGE1 is not inactivated in the lung it could serve as a circulating hormone.
    [Abstract] [Full Text] [Related] [New Search]